Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-09
2007-01-09
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S309000
Reexamination Certificate
active
10482572
ABSTRACT:
The invention related to novel compounds of Formula (I) or a salt, solvate or prodrug thereof, wherein R1, R2, R3, n and m are as described in the specification, useful in the treatment of adisease or condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to methods for preparing compounds of Formula (I) and their use as medicaments in the treatment of diseases mediated by glucokinase.
REFERENCES:
patent: 4146631 (1979-03-01), Ford et al.
patent: 5849735 (1998-12-01), Albright et al.
patent: 6388071 (2002-05-01), Mahaney
patent: 2005/0080106 (2005-04-01), Boyd et al.
patent: 0 619 116 (1994-03-01), None
patent: 1 048 659 (2000-11-01), None
patent: 1 400 540 (2000-11-01), None
patent: 0 620 216 (2003-01-01), None
patent: 1 336 607 (2003-08-01), None
patent: 1357116 (2003-10-01), None
patent: 1600442 (2005-11-01), None
patent: 2 385 328 (2003-08-01), None
patent: 5-7021320 (1982-02-01), None
patent: 8-143565 (1996-06-01), None
patent: 08 173525 (1996-07-01), None
patent: 10-212271 (1998-08-01), None
patent: 11171848 (1999-06-01), None
patent: WO-95/20578 (1995-08-01), None
patent: WO 96/11902 (1996-04-01), None
patent: WO-96/22282 (1996-07-01), None
patent: WO-96/22293 (1996-07-01), None
patent: WO-96/22294 (1996-07-01), None
patent: WO-96/22295 (1996-07-01), None
patent: WO-96/41795 (1996-12-01), None
patent: WO-97/36480 (1997-03-01), None
patent: WO-97/49707 (1997-12-01), None
patent: WO-97/49708 (1997-12-01), None
patent: WO-98/24771 (1997-12-01), None
patent: WO-98/34632 (1998-08-01), None
patent: WO-98/45242 (1998-10-01), None
patent: WO-99/38845 (1999-08-01), None
patent: WO-99/62901 (1999-12-01), None
patent: WO-00/02850 (2000-01-01), None
patent: WO 00/26202 (2000-05-01), None
patent: WO 00/39118 (2000-07-01), None
patent: WO-00/58293 (2000-10-01), None
patent: WO-01/16097 (2001-03-01), None
patent: WO 01/19788 (2001-03-01), None
patent: WO-01/20327 (2001-03-01), None
patent: WO-01/32639 (2001-05-01), None
patent: WO-03/095438 (2001-05-01), None
patent: WO-01/44216 (2001-06-01), None
patent: WO 01/83465 (2001-11-01), None
patent: WO-01/83478 (2001-11-01), None
patent: WO-01/85706 (2001-11-01), None
patent: WO-01/85707 (2001-11-01), None
patent: WO-02/08209 (2002-01-01), None
patent: WO-02/14312 (2002-02-01), None
patent: WO 02/24682 (2002-03-01), None
patent: WO-02/28835 (2002-04-01), None
patent: WO-02/46173 (2002-06-01), None
patent: WO-02/48106 (2002-06-01), None
patent: WO 03/000262 (2003-01-01), None
patent: WO-03/000267 (2003-01-01), None
patent: WO 03/015774 (2003-02-01), None
patent: WO-03/080585 (2003-02-01), None
patent: WO 03/047626 (2003-06-01), None
patent: WO-03/055482 (2003-07-01), None
patent: WO 03/082838 (2003-10-01), None
patent: WO-03/095438 (2003-11-01), None
patent: WO-03/097824 (2003-11-01), None
patent: WO-2004/002481 (2004-01-01), None
patent: WO-94/04525 (2004-03-01), None
patent: WO 2004/045614 (2004-06-01), None
patent: WO 2004/046139 (2004-06-01), None
patent: WO 2004/050645 (2004-06-01), None
patent: WO 2004/052869 (2004-06-01), None
patent: WO 2004/063179 (2004-07-01), None
patent: WO 2004/063194 (2004-07-01), None
patent: WO 2004/072031 (2004-08-01), None
patent: WO 2004/072066 (2004-08-01), None
patent: WO 2004/076420 (2004-09-01), None
patent: WO 2004/081001 (2004-09-01), None
patent: WO 2004/0855406 (2004-10-01), None
patent: WO 2004/110375 (2004-12-01), None
patent: WO 2005/044801 (2005-05-01), None
patent: WO 2005/049019 (2005-06-01), None
patent: WO 2005/054200 (2005-06-01), None
patent: WO 2005/054233 (2005-06-01), None
patent: WO 2005/056530 (2005-06-01), None
patent: WO 2005/063738 (2005-07-01), None
patent: WO 2005/066145 (2005-07-01), None
patent: WO 2005/080359 (2005-09-01), None
patent: WO 2005/080360 (2005-09-01), None
patent: WO 2005/090332 (2005-09-01), None
patent: WO 2005/095417 (2005-10-01), None
patent: WO 2005/095418 (2005-10-01), None
patent: WO 2005/103021 (2005-11-01), None
patent: WO 2005/121110 (2005-12-01), None
patent: WO 2005/123132 (2005-12-01), None
patent: WO 2006/016174 (2006-02-01), None
patent: WO 2006/016178 (2006-02-01), None
patent: WO 2006/016194 (2006-02-01), None
Shiota et. al., “Glucokinase Gene Locus Transgenic Mice Are Resistant to the Development of Obesity-Induced Type 2 Diabetes”, Diabetes, vol. 50, Mar. 2001.
Hashimoto, Y. et al., “Evaluation of Differentiation-Inducing Activity of Retinoids on Human Leukemia Cell Lines HL-60 and NB4,” Biol. Pharm. Bull., vol. 19, No. 10, (1996).
Alvarez, E., et al., “Expression of the Glucagon-Like Peptide-1 Receptor Gene in Rat Brain,” Journal of Neurochemistry, vol. 66, No. 3, pp. 920-927 (1996).
Alvarez, E., et al., “Evidence that Glucokinase Regulatory Protein is Expressed and Interacts with Glucokinase in Rat Brain,” Journal of Neurochemistry, vol. 80, pp. 45-53 (2002).
Brocklehurst, K.J. et al., “Stimulation of Hepatocyte Glucose Metabolism by Novel Small Molecule Glucokinase Activators,” Diabetes, vol. 53, pp. 535-541 (2004).
Bell, G.I. et al., “Glucokinase Mutations, Insulin Secretion, and Diabetes Mellitus,” Annu. Rev. Physiol., vol. 58, pp. 171-186 (1996).
Caro, J.F. et al., “Liver Glucokinase: Decreased Activity in Patients with Type II Diabetes,” Horm. Metab. Res., vol. 27, pp. 19-22 (1995).
Christesen, H.B.T. et al., “The Second Activating Glucokinase Mutation (A456V): Implications for Glucose Homeostasis and Diabetes Therapy,” Diabetes, vol. 51, pp. 1240-1246 (2002).
Corbett, W.L., “Glucokinase Activators: Discovery of Novel, Orally Active Glucose Lowering Agents,” Cambridge Healthtech Institute's Eleventh Annual Molecular Medicine Tri-Conference, (2004).
Qian-Cutrone, J. et al., “Glucolipsin A and B, Two New Glucokinase Activators Produced by Streptomyces Purpurogeniscleroticus and Nocardia Vaccinii,” The Journal of Antibiotics, vol. 52, No. 3, pp. 245-255 (1999).
Defronzo, R.A., “The Triumvirate: B-Cell, Muscle, Liver: A Collusion Responsible for NIDDM,” Diabetes, vol. 37, pp. 667-687 (1988).
Desai, U.J. et al., “Phenotypic Correction of Diabetic Mice by Adenovirus-Mediated Glucokinase Expression,” Diabetes, vol. 50, pp. 2287-2295 (2001).
Ferre, T. et al., “Correction of Diabetic Alterations by Glucokinase,” Proc. Natl. Acad. Sci. USA, vol. 93, pp. 7225-7230 (1996).
Froguel, P. et al., “Familial Hyperglycemia Due to Mutations in Glucokinase—Definition of a Subtype of Diabetes Mellitus,” The New England Journal of Medicine, vol. 328, No. 10, pp. 697-702 (1993).
Fujimoto, K. et al., “Administration of D-Glucosamine into the Third Cerebroventricle Induced Feeding Accompanied by Hyperglycemia in Rats,” Life Sciences, vol. 37, pp. 2475-2482 (1985).
Glaser, B. et al., “Familial Hyperinsulinism Caused by an Activating Glucokinase Mutation,” The New England Journal of Medicine, vol. 338, No. 4, pp. 226-230 (1998).
Grimsby, J. et al., “Glucokinase Activators: Potential Treatment for Type 2 Diabetes,” Roche Literature.
Grimsby, J. et al., “Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy,” Science, vol. 301, pp. 370-373 (2003).###.
Kurata, K. et al., “Structural Evaluation of Glucose Analogues on Feeding Elicitation in Rat,” Metabolism, vol. 38, No. 1, pp. 46-51 (1989).
Kurata, K. et al., “D-Glucose Suppression of Eating After Intra-Third Ventricle Infusion in Rat,” Physiology & Behavior, vol. 37, pp. 615-620 (1986).
Levin, B.E. et al., “Differential Effects of Diet and Obesity on High and Low Affinity Sulfonyturea Binding Sites in the Rat Brain,” Brain Research, vol. 739, pp. 293-300 (1996).
Levin, B.E. et al., “In Vivo and In Vitro Regulation of [3H]glyburide Binding to Brain Sulfonylurea Receptors in Obesity-prone and Resistant Rats by Glucose,” Brain Research, vol. 776, pp. 146-153 (1997).
Levin, B.E. et al., “Reduced Glucose-Induced Neuronal Activation in the
Allen Joanne Victoria
Caulkett Peter William Rodney
Currie Gordon Stuart
Gaskin Harold
Hargreaves Rodney Brian
AstraZeneca AB
Barker Michael
Morgan & Lewis & Bockius, LLP
Saeed Kamal A.
LandOfFree
Amino nicotinate derivatives as glucokinase (GLK) modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amino nicotinate derivatives as glucokinase (GLK) modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino nicotinate derivatives as glucokinase (GLK) modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3725745